B-cell prolymphocytic leukemia: an enduring bona fide entity.
B-cell prolymphocytic leukemia
Lymphoproliferative disorders
Prolymphocytes
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
26 May 2024
26 May 2024
Historique:
received:
25
01
2024
accepted:
08
04
2024
revised:
03
04
2024
medline:
26
5
2024
pubmed:
26
5
2024
entrez:
26
5
2024
Statut:
aheadofprint
Résumé
B-cell prolymphocytic leukemia (B-PLL) was recognized as a distinct entity in the fourth edition of the World Health Organization (WHO) classification for hematolymphoid neoplasms (WHO-HAEM4); however, its de novo presentation has been removed from the upcoming 5th edition classification (WHO-HAEM5). We present a case of a 65-year-old man with leukocytosis, fatigue, and no organomegaly by imaging. Bone marrow examination showed a prolymphocytoid population comprising 78% of the marrow elements. After thorough exclusion of other entities by clinical parameters and ancillary methods, we concluded that this case represents a de novo case of B-PLL.
Identifiants
pubmed: 38796826
doi: 10.1007/s12185-024-03774-4
pii: 10.1007/s12185-024-03774-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Japanese Society of Hematology.
Références
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. Springer US; 2022.
Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. Blood. 2022.
Swerdlow S, Campo E, Harris N, Al E. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4t. Lyon, France: IARC; 2017.
Melo J V., Catovsky D, Galton DAG. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia: II. patterns of evolution of ‘prolymphocytoid’ transformation. Br J Haematol. 1986;64:77–86.
Cartron G, Linassier C, Bremond JL, Desablens B, Georget MT, Fimbel B, et al. CD5 negative B-cell chronic lymphocytic leukemia: clinical and biological features of 42 cases. Leuk Lymphoma. 1998;31:209–16.
doi: 10.3109/10428199809057600
pubmed: 9720730
Schlette E, Bueso-Ramos C, Giles F, Glassman A, Hayes K, Medeiros LJ. Mature B-cell leukemias with more than 55% prolymphocytes: a heterogeneous group that includes an unusual variant of mantle cell lymphoma. Am J Clin Pathol. 2001;115:571–81.
doi: 10.1309/PPK0-TJUK-1UAR-3194
pubmed: 11293906
Menter T, Dirnhofer S, Tzankov A. LEF1: A highly specific marker for the diagnosis of chronic lymphocytic B cell leukaemia/small lymphocytic B cell lymphoma. J Clin Pathol. 2015;68:473–8.
doi: 10.1136/jclinpath-2015-202862
pubmed: 25713417
Ting YS, Smith SABC, Brown DA, Dodds AJ, Fay KC, Ma DDF, et al. CD200 is a useful diagnostic marker for identifying atypical chronic lymphocytic leukemia by flow cytometry. Int J Lab Hematol. 2018;40:533–9.
doi: 10.1111/ijlh.12857
pubmed: 29806244
Flatley E, Chen AI, Zhao X, Jaffe ES, Dunlap JB, Pittaluga S, et al. Aberrations of MYC are a common event in B-cell prolymphocytic leukemia. Am J Clin Pathol. 2014;142:347–54.
doi: 10.1309/AJCPUBHM8U7ZFLOB
pubmed: 25125625
Chapiro E, Pramil E, Diop M, Roos-Weil D, Dillard C, Gabillaud C, et al. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53. Blood. 2019;134:1821–31.
pubmed: 31527074
Del Giudice I, Osuji N, Dexter T, Brito-Babapulle V, Parry-Jones N, Chiaretti S, et al. B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures. Leukemia. 2009;23:2160–7.
doi: 10.1038/leu.2009.137
pubmed: 19641528
Put N, Van Roosbroeck K, Konings P, Meeus P, Brusselmans C, Rack K, et al. Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course. Ann Hematol. 2012;91:863–73.
doi: 10.1007/s00277-011-1393-y
pubmed: 22205151
Salido M, Baró C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood. 2010;116:1479–88.
doi: 10.1182/blood-2010-02-267476
pubmed: 20479288
Hu Z, Medeiros LJ, Chen Z, Chen W, Li S, Konoplev SN, et al. Mantle cell lymphoma with MYC rearrangement: a report of 17 patients. Am J Surg Pathol. 2017;41:216–24.
doi: 10.1097/PAS.0000000000000758
pubmed: 27776009
NCCN Guidelines Version 2.2023 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Shvidel L, Shtalrid M, Bassous L, Klepfish A, Vorst E, Berrebiz A. B-Cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course. Leuk Lymphoma. 1999;33:169–79.
doi: 10.3109/10428199909093739
pubmed: 10194135